BioCentury
ARTICLE | Clinical News

ABX464: Phase IIa started

June 6, 2016 7:00 AM UTC

Abivax began the double-blind, placebo-controlled, European Phase IIa ABX464-004 trial to evaluate 50 mg oral ABX464 once daily for 28 days with Prezista darunavir plus ritonavir or with Prezista plu...